Combination of ATRAP deletion and angiotensin II accelerates DKD progression, which may also accelerate DKD research.

CommentOn

Hypertens Res. 2024 Jan;47(1):55-66. doi: 10.1038/s41440-023-01496-4

COI Statement

Compliance with ethical standards. Conflict of interest: The authors declare no competing interests.

References:

• Tamura K, Wakui H, Maeda A, Dejima T, Ohsawa M, Azushima K, et al. The physiology and pathophysiology of a novel angiotensin receptor-binding protein ATRAP/Agtrap. Curr Pharm Des. 2013;19:3043–8.
• Tamura K, Azushima K, Kinguchi S, Wakui H, Yamaji T. ATRAP, a receptor-interacting modulator of kidney physiology, as a novel player in blood pressure and beyond. Hypertens Res. 2022;45:32–39.
• Tsukamoto S, Suzuki T, Wakui H, Uehara T, Ichikawa J, Okuda H, et al. Angiotensin II type 1 receptor-associated protein in immune cells: a possible key factor in the pathogenesis of visceral obesity. Metabolism. 2023;149:155706.
• Haruhara K, Suzuki T, Wakui H, Azushima K, Kurotaki D, Tamura K, et al. Deficiency of the kidney tubular angiotensin II type1 receptor-associated protein ATRAP exacerbates streptozotocin-induced diabetic glomerular injury via reducing protective macrophage polarization. Kidney Int. 2022;101:912–28.
• Taguchi S, Azushima K, Yamaji T, Suzuki T, Wakui H, Tamura K, et al. Angiotensin II type 1 receptor-associated protein deletion combined with angiotensin II stimulation accelerates the development of diabetic kidney disease in mice on a C57BL/6 strain. Hypertens Res. 2024;47:55–66.